Jennifer Kahler
Pfizer (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, HER2/EGFR in Cancer Research, Cancer Mechanisms and Therapy, Cancer Treatment and Pharmacology, Acute Myeloid Leukemia Research
Most-Cited Works
- → Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib(2006)439 cited
- → Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin(2011)200 cited
- → OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models(2006)80 cited
- → Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics(2013)26 cited
- → Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes(2015)24 cited
- → Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2(2011)22 cited
- → Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia(2020)21 cited
- → Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics(2013)17 cited
- → Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases(2013)15 cited
- → High-Throughput Screening for mTORC1/mTORC2 Kinase Inhibitors Using a Chemiluminescence-Based ELISA Assay(2009)7 cited